Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

08 170,730,621 Receivables from stockholders (50,000 ) (50,000 ) Accumulated deficit (146,892,807 ) (139,847,326 ) Accumulated other comprehensive (loss) income (864,981 ) 157,531 Total stockholders' equity 23,566,919 31,034,754 Total liabilities and stockholders' equity $ 32,264,741 $ 39,775,021 INOVIO BIOMEDICAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months EndedJune 30, Six Months EndedJune 30, 2008 2007 2008 2007 Revenue: License fee and milestone payments $ 203,924 $ 209,265 $ 396,753 $ 443,754 Revenue under collaborative research anddevelopment arrangements

459,110 286,312 919,295 534,302 Grant and miscellaneous revenue — — — 21,423 Total revenue 663,034 495,577 1,316,048 999,479 Operating expenses: Research and development 1,679,264 2,907,836 3,276,652 5,424,247 General and administrative 3,086,180 2,344,551 5,487,685 4,635,712 Total operating expenses 4,765,444 5,252,387 8,764,337 10,059,959 Loss from operations (4,102,410 ) (4,756,810 ) (7,448,289 ) (9,060,480 ) Interest income 191,371 286,792 490,120 509,860 Other income (expense) (112,733 ) 727,305 (87,312 ) 1,066,610 Net loss (4,023,772 ) (3,742,713 ) (7,045,481 ) (7,484,010 ) Imputed and declared dividends on preferredstock

— (8,244 ) — (23,335 ) Net loss attributable to common stockholders

  • (4,023,772 ) $ (3,750,957 ) $ (7,045,481 ) $ (7,507,345 ) Amounts per common share — basic and diluted:

Net loss per share attributable to common stockholders

  • (0.09 ) $ (0.09 ) $ (0.16 ) $ (0.19 ) Weighted average number of common shares outstanding — basic and diluted

43,874,739 40,674,947 43
'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 1APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 60929 2